Efficacy and Safety of Ningmitai Capsule in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Chronic Prostatitis
About this trial
This is an interventional treatment trial for Chronic Prostatitis
Eligibility Criteria
Inclusion Criteria: Aged 18-60 years old male patients; Patients with long-term, repeated pelvic discomfort or pain (NIH-CPSI pain score 4), lasting more than 3 months, may be accompanied by varying degrees of voiding symptoms and sexual dysfunction. Clinical diagnosis: type III prostatitis. Exclusion Criteria: Use of any antibiotics and 1 receptor blockers in the past two weeks; Suffering from seminal vesiculitis, epididymitis, varicocele and prostate, bladder, urethra and other tumors and other diseases affecting bladder function; Have received TURP, TUIP, internal cystotomy, transurethral hyperthermia/radiofrequency ablation/balloon dilatation, open prostatectomy, or any other prostate surgery and treatment, such as cryotherapy or hyperthermia; Patients with severe cardiovascular and cerebrovascular, liver, kidney and hematopoietic system diseases and mental illness; Known to be allergic to Ningmitai capsule or some of its components; Involuntary, unable to cooperate with the completion of the study.
Sites / Locations
- The first affiliated hospital of Anhui medical university
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Active Comparator
Ningmitai Capsule group
Tamsulosin Hydrochloride Sustained-release Capsules group
Combined group
Patients take Ningmitai capsule, 0.38 g/capsule, tid, 4 capsules each time, after meals, for 8 weeks.
Patients take Tamsulosin Hydrochloride Sustained-release Capsules ,0.2 mg/capsule, once daily, 1 capsule each time, for 8 weeks.
Patients take Ningmitai capsule, 0.38 g/capsule, tid, 4 capsules each time, after meals, for 8 weeks and Tamsulosin Hydrochloride Sustained-release Capsules ,0.2 mg/capsule, once daily, 1 capsule each time, for 8 weeks.